Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Nuclear Medicine, University Hospital Münster, Münster, Germany; Department of Nuclear Medicine, University Hospital Essen, Essen, Germany; West German Cancer Centre, Universitätsklinikum Essen, Hufelandstr. 55, 45147 Essen, Germany; German Cancer Consortium (DKTK), German Cancer Research Center, Im Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
PET Clin. 2021 Jul;16(3):383-390. doi: 10.1016/j.cpet.2021.03.003.
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinical trial data, comparing and contrasting radiotracers and reporting outcome-based data are necessary to further increase the implementation of this very promising imaging modality.
前列腺特异膜抗原 - 正电子发射断层扫描/计算机断层扫描（PSMA-PET/CT）是前列腺癌成像的首选检查方法。PSMA-PET/CT 具有很高的诊断准确性，可在疾病复发的早期阶段检测到疾病，此时根治的可能性最大。一些 PSMA 放射性配体已在临床常规中得到确立，目前只有有限的数据，而且目前还没有一种示踪剂可以明显优于其他示踪剂。需要进一步的临床试验数据，比较和对比放射性示踪剂并报告基于结果的数据，以进一步增加这种非常有前途的成像方式的应用。
